Opioid prescribing varies widely among urologists

Publication
Article
Urology Times JournalVol 47 No 10
Volume 47
Issue 10

"Clearly, we are overprescribing and in some cases very seriously overprescribing nationally-regardless of procedure," says study author Jennifer A. Robles, MD.

irissca - stock.adobe.com

irissca - stock.adobe.com

Researchers expected some variation and some overprescribing when they looked nationally at urologists’ opioid prescribing patterns for common urologic surgeries. But the degree of variation-from zero to 7,560 mg oral morphine equivalents-as well as the vast majority of overprescribing even for minimally invasive urologic procedures was alarming, according to Jennifer A. Robles, MD.

“For a long time, the focus in the opioid crisis has been on chronic pain treatment. Now, there’s increasing recognition that acute pain opioid prescriptions are contributing to the crisis. There’s increasing focus on surgical prescribing. Where this is relevant is that a number of studies have shown that approximately 6% to 8% of surgical patients across specialties become chronic opioid users after getting opioids for surgery,” said Dr. Robles, a laparoscopic/endourology fellow at the University Medical Center at Vanderbilt and VA Quality Scholar at the Tennessee Valley Healthcare System, Nashville. The research was presented at the AUA annual meeting in Chicago.

Studies also have shown that most patients aren’t using most of the pills that surgeons prescribe, resulting in pills being diverted into the community.

Both factors contribute to the epidemic, said Dr. Robles, working with Matthew J. Resnick, MD, MPH, MMHC, and colleagues.

Also see: It’s urologists’ turn to do something about opioids

Dr. Robles and colleagues analyzed national VA data on nearly 20,000 urologic surgery patients from 2014 through 2016. They looked at opioid prescribing in the specialty’s most common inpatient procedures: open or minimally invasive nephrectomy, prostatectomy, cystectomy, transurethral resection of the prostate, or photovaporization of the prostate.

The authors accounted for urologic surgeons’ prescribing for different opioid-containing medications, such as oxycodone or hydrocodone, and standardized those by converting them to oral morphine equivalents.

“To put more context on an acceptable number for oral morphine equivalents, multiple states are issuing limits to prescribing and those limits are centered around 200 oral morphine equivalents,” she said. “The state of Tennessee just passed a law last year limiting acute prescribing to 180 [oral morphine equivalents] and Minnesota has put a 200 cutoff, so we used 200 or less as our guide for what optimal prescribing should be.”

Next: According to this study on urologic surgery, 5% of the patient population was given more than 600 mg of morphine equivalentsAccording to this study on urologic surgery, 5% of the patient population was given more than 600 mg of morphine equivalents. The median prescribed dose across all procedures was 225 mg.

“Clearly, we are overprescribing and in some cases very seriously overprescribing nationally-regardless of procedure,” Dr. Robles said.

Urologists are overprescribing opioids for not only open but also minimally invasive procedures. In fact, they’re prescribing about the same doses whether patients have open or less invasive procedures, according to Dr. Robles.

That’s significant for a couple of reasons, Dr. Robles said.

Dr. Robles cited a study published last year that shows when patients are prescribed more pain pills, they take more (JAMA Surgery 2019; 154:e184234).

“On average for every additional pill you give them, they take an extra half pill,” Dr. Robles said. “Secondly, if those patients truly have less pain and are using less pain medication overall than open surgery patients, that means they have a whole bottle of pain pills sitting on their counter that is at risk for being diverted into the community, stolen, given away, or taken by someone in the family.”

Dr. Robles and colleagues also looked at whether there were factors, including age, gender, length of hospital stay, location, facility type, and preoperative use of opioids, that might predict why some patients were getting a lot of pain pills and others weren’t.

Read: Post-procedure opioid Rx may be unnecessary

They found those in the highest quartile of prescribed oral morphine equivalent dose were more likely to be younger, had slightly increased length of stay, had undergone surgery in a teaching facility or in the South, or had filled an opioid prescription within 90 days before surgery.

Preoperative opioid use explained only 5% of the observed variance.

“It’s a factor but it’s not a huge factor,” Dr. Robles said. “What was a huge factor was location.”

New York, for example, prescribes in the highest quartile 13% or less of the time. Other states might prescribe in the highest quartile 50% of the time.

Regional prescribing trends in urologic surgery closely match national CDC prescription data across all surgical settings, according to Dr. Robles.

Certain states and regions like the Southeast (Tennessee and below) are very high prescribers in all settings and urology, while other areas, like the Northeast, are very low prescribers on both maps, according to Dr. Robles.

Urologic prescribing data suggest that whether urologists are high or low prescribers, it’s likely less due to individual patients’ demands or needs and has more to do with how urologists were trained or their cultural tradition around prescribing.

“That’s exciting because it’s modifiable with education and more work to publish national data,” she said.

National data show urologists how others in the specialty are prescribing opioids for the same procedures. When urologists realize they’re outliers, some will change, according to Dr. Robles.

We want to hear from you! Have you changed your opioid prescribing habits? Let us know at urology_times@mmhgroup.com

Related Videos
Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"
Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"
Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"
Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"
Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.